Search
01/01/2025
Tirzepatide for adults living with obesity
Franco, JVA, Guo, Y, Varela, LB, Aqra, Z, Alhalahla, M, Rodriguez, MM, Oscco, ELS, Araujo, BP, Banda, S, Liquitay, CME, Bracchiglione, J, Meza, N, Madrid, E. Tirzepatide for adults living with obesity. COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2025; (10)DOI:10.1002/14651858.CD016018. PMID:41161687. IF:9.400(Q1/1D).
01/01/2025
Digoxin initiation after an acute heart failure episode and its association with post-discharge outcomes: an international multicenter analysis
Miró, O, Mojarro, EM, Huré, G, Llorens, P, Gil, V, Alquézar-Arbé, A, Bibiano, C, González, NC, Massó, M, Strebel, I, Espinosa, B, Masó, SM, Wussler, D, Shrestha, S, Lopez-Ayala, P, Jacob, J, Millán, J, Andueza, JA, Alonso, H, Pàmies, SL, Cerda, JF, Martínez, CP, Herrero, P, Peacock, WF, Mueller, C. Digoxin initiation after an acute heart failure episode and its association with post-discharge outcomes: an international multicenter analysis. Internal and Emergency Medicine. 2025; 20(1)DOI:10.1007/s11739-024-03744-y. PMID:39174687. IF:3.800(Q1/2D).
01/01/2025
Semaglutide for adults living with obesity
Bracchiglione, J, Meza, N, Franco, JVA, Liquitay, CME, Novik, AV, Vargas, MO, Lazcano, G, Poloni, D, Langlotz, FR, Roqué-Figuls, M, Munoz, SR, Madrid, E. Semaglutide for adults living with obesity. COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2025; (10)DOI:10.1002/14651858.CD015092.pub2. PMID:41161683. IF:9.400(Q1/1D).
31/12/2024
Early identification of the nosocomial spread of vancomycin-resistant Enterococcus faecium by Fourier-transform infrared spectroscopy and performance comparison with PFGE and WGS
Pitart, C, Piquet, M, Burgwinkel, T, Del Pino, RA, Rubio, M, Aguilar, M, De Gea, S, Pulgarín, A, Campo, I, Torralbo, B, Parejo, R, Valls, S, Fortes, I, Santana, G, Rubio, E, Vilella, A, Del Rio, A, Martinez, JA, Miró, E, Navarro, F, Espasa, M, Casals-Pascual, C, Vila, J, Higgins, PG, Roca, I. Early identification of the nosocomial spread of vancomycin-resistant Enterococcus faecium by Fourier-transform infrared spectroscopy and performance comparison with PFGE and WGS. Emerging Microbes & Infections. 2024; 13(1)DOI:10.1080/22221751.2024.2392659. PMID:39137261. IF:7.500(Q1/1D).
31/12/2024
Periodontal diseases and cardiovascular diseases, diabetes, and respiratory diseases: Summary of the consensus report by the European Federation of Periodontology and WONCA Europe
Herrera, D, Sanz, M, Shapira, L, Brotons, C, Chapple, I, Frese, T, Graziani, F, Hobbs, FDR, Huck, O, Hummers, E, Jepsen, S, Kravtchenko, O, Madianos, P, Molina, A, Ungan, M, Vilaseca, J, Windak, A, Vinker, S. Periodontal diseases and cardiovascular diseases, diabetes, and respiratory diseases: Summary of the consensus report by the European Federation of Periodontology and WONCA Europe. European Journal of General Practice. 2024; 30(1)DOI:10.1080/13814788.2024.2320120. PMID:38511739. IF:2.500(Q1/1D).
31/12/2024
Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting
Koyner, JL, Arndt, C, de Irujo, JBM, Coelho, S, de la Peña, MGM, di Girolamo, L, Joannidis, M, Jorge-Monjas, P, Koch, C, Lobaz, S, Meyer, A, Ostermann, M, Pertica, N, Prowle, JR, Silversides, J, Zarbock, A, Echeverri, J, Harenski, K, Forni, LG. Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting. RENAL FAILURE. 2024; 46(1)DOI:10.1080/0886022X.2024.2345747. PMID:38666354. IF:3.000(Q1/3D).
31/12/2024
Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Girolomoni, G, Feldman, SR, Egeberg, A, Puig, L, Jung, J, Jung, H, Lee, Y. Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). JOURNAL OF DERMATOLOGICAL TREATMENT. 2024; 35(1)DOI:10.1080/09546634.2024.2434091. PMID:39626886. IF:3.900(Q1/2D).
31/12/2024
Modelling the spatial risk of malaria through probability distribution of Anopheles maculipennis s.l. and imported cases
Taheri, S, González, MA, Ruiz-López, MJ, Magallanes, S, Delacour-Estrella, S, Lucientes, J, Bueno-Marí, R, Martínez-de la Puente, J, Bravo-Barriga, D, Frontera, E, Polina, A, Martinez-Barciela, Y, Pereira, JM, Garrido, J, Aranda, C, Marzal, A, Ruiz-Arrondo, I, Oteo, JA, Ferraguti, M, Gutíerrez-López, R, Estrada, R, Miranda, MA, Barceló, C, Morchón, R, Montalvo, T, Gangoso, L, Goiri, F, García-Pérez, AL, Ruiz, S, Fernandez-Martinez, B, Gómez-Barroso, D, Figuerola, J. Modelling the spatial risk of malaria through probability distribution of Anopheles maculipennis s.l. and imported cases. Emerging Microbes & Infections. 2024; 13(1)DOI:10.1080/22221751.2024.2343911. PMID:38618930. IF:7.500(Q1/1D).
27/12/2024
Point-of-care additive manufacturing: state of the art and adoption in Spanish hospitals during pre to post COVID-19 era
Valls-Esteve, A, García, RI, Bellmunt, A, Eguiraun, H, Jauregui, I, del Amo, C, Adell-Gomez, N, Krauel, L, Munuera, J. Point-of-care additive manufacturing: state of the art and adoption in Spanish hospitals during pre to post COVID-19 era. 3d Printing In Medicine. 2024; 10(1)DOI:10.1186/s41205-024-00244-9. PMID:39729163. IF:(Q/D).
21/12/2024
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials
Río, P, Zubicaray, J, Navarro, S, Gálvez, E, Sánchez-Domínguez, R, Nicoletti, E, Sebastian, E, Rothe, M, Pujol, R, Bogliolo, M, John-Neek, P, Bastone, AL, Schambach, A, Wang, W, Schmidt, M, Larcher, L, Segovia, JC, Yáñez, RM, Alberquilla, O, Diez, B, Fernández-García, M, García-García, L, Ramírez, M, Galy, A, Lefrere, F, Cavazzana, M, Leblanc, T, de Andoin, NG, López-Almaraz, R, Catala, A, Barquinero, J, Rodríguez-Perales, S, Rao, G, Surrallés, J, Soulier, J, Díaz-de-Heredia, C, Schwartz, JD, Sevilla, J, Bueren, JA. Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. LANCET. 2024; 404(10471)DOI:10.1016/S0140-6736(24)01880-4. PMID:39642902. IF:88.500(Q1/1D).
20/12/2024
Effectiveness of an Exercise and Educational-Based Prehabilitation Program in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy (PREOptimize) on Functional Outcomes: A Randomized Controlled Trial
Casanovas-alvarez, A, Estanyol, B, Ciendones, M, Padròs, J, Cuartero, J, Barnadas, A, García-Valdecasas, B, González-Colom, R, Sebio-García, R, Masià, J. Effectiveness of an Exercise and Educational-Based Prehabilitation Program in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy (PREOptimize) on Functional Outcomes: A Randomized Controlled Trial. PHYSICAL THERAPY. 2024; 104(12)DOI:10.1093/ptj/pzae151. PMID:39423256. IF:3.300(Q1/1D).
19/12/2024
Guillain-Barre syndrome
Leonhard, SE, Papri, N, Querol, L, Rinaldi, S, Shahrizaila, N, Jacobs, BC. Guillain-Barre syndrome. Nature Reviews Disease Primers. 2024; 10(1)DOI:10.1038/s41572-024-00580-4. PMID:39702645. IF:60.600(Q1/1D).
19/12/2024
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis (vol 15, 1480676, 2024)
Rodríguez-Jorge, F, Fernández-Velasco, JI, Villarrubia, N, Gracia-Gil, J, Fernández, E, Meca-Lallana, V, Díaz-Pérez, C, de la Maza, SS, Pacheco, EM, Quiroga, A, Ramió-Torrentà, L, Martínez-Yélamos, S, Bau, L, Monreal, E, López-Real, A, Rodero-Romero, A, Borrega, L, Díaz, S, Eguía, P, Espiño, M, Chico-García, JL, Barrero, FJ, Martínez-Ginés, ML, García-Domínguez, JM, de la Fuente, S, Moreno, I, Sainz-Amo, R, Mañé-Martínez, MA, Caminero, A, Castellanos-Pinedo, F, López, AG, Labiano-Fontcuberta, A, Ayuso, L, Abreu, R, Hernández, MA, Meca-Lallana, J, Martín-Aguilar, L, Garcia, AM, Masjuan, J, Costa-Frossard, L, Villar, LM. Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis (vol 15, 1480676, 2024). Frontiers in Immunology. 2024; 15DOI:10.3389/fimmu.2024.1535051. PMID:39749346. IF:5.900(Q1/2D).
18/12/2024
Myocardial Injury in Patients with Hip Fracture A HIP ATTACK Randomized Trial Substudy
Borges, FK, Guerra-Farfan, E, Bhandari, M, Patel, A, Slobogean, G, Feibel, RJ, Sancheti, PK, Tiboni, ME, Balaguer-Castro, M, Tandon, V, Tomas-Hernandez, J, Sigamani, A, Sigamani, A, Szczeklik, W, Mcmahon, SJ, Sleczka, P, Ramokgopa, MT, Adinaryanan, S, Umer, M, Jenkinson, RJ, Lawendy, A, Popova, E, Nur, AN, Wang, CY, Vizcaychipi, M, Biccard, BM, Ofori, S, Spence, J, Duceppe, E, Marcucci, M, Harvey, V, Balasubramanian, K, Vincent, J, Tonelli, AC, Devereaux, PJ, HIP ATTACK Investigators. Myocardial Injury in Patients with Hip Fracture A HIP ATTACK Randomized Trial Substudy. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME. 2024; 106(24)DOI:10.2106/JBJS.23.01459. PMID:39052767. IF:4.300(Q1/1D).
17/12/2024
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study
Piedra, A, Martínez-Recio, S, Hernández, A, Morán, T, Arriola, E, Recuero-Borau, J, Cobo, M, Cordeiro, P, Mosquera, J, Fernández, M, García-Campelo, R, Calles, A, Alvarez, R, Zapata-García, M, Isla, D, Callejo, A, Iranzo, P, Serra-López, J, Barba, A, Sullivan, I, Felip, E, Majem, M. First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study. Frontiers in Oncology. 2024; 14DOI:10.3389/fonc.2024.1510278. PMID:39741981. IF:3.300(Q2/4D).
17/12/2024
Differential Expression Analyses on Human Aortic Tissue Reveal Novel Genes and Pathways Associated With Abdominal Aortic Aneurysm Onset and Progression
Temprano-Sagrera, G, Peypoch, O, Soto, B, Dilmé, J, Juscafresa, LC, Davtian, D, Estadella, MD, Nieto, L, Brown, A, Escudero, JR, Viñuela, A, Camacho, M, Sabater-Lleal, M. Differential Expression Analyses on Human Aortic Tissue Reveal Novel Genes and Pathways Associated With Abdominal Aortic Aneurysm Onset and Progression. Journal of the American Heart Association. 2024; 13(24)DOI:10.1161/JAHA.124.036082. PMID:39655704. IF:5.300(Q1/2D).
16/12/2024
International Alliance of Urolithiasis (IAU) consensus on miniaturized percutaneous nephrolithotomy ( vol 11 , 70 , 2024)
Zeng, GH, Zhong, W, Mazzon, G, Zhu, W, Lahme, S, Khadgi, S, Desai, J, Agrawal, M, Schulsinger, D, Gupta, M, Montanari, E, Martinez, JML, Almousawi, S, Malonzo, VEF, Sriprasad, S, Durutovic, O, Arumuham, V, Ferretti, S, Kamal, W, Xu, KW, Cheng, F, Gao, XF, Cheng, JW, Somani, B, Duvdevani, M, Git, KA, Seitz, C, Bernardo, N, Ibrahim, TAA, Aquino, A, Yasui, T, Fiori, C, Knoll, T, Papatsoris, A, Gadzhiev, N, Zhanbyrbekuly, U, Angerri, O, Ramos, HL, Saltirov, I, Moussa, M, Giusti, G, Vicentini, F, Suarez, EB, Pearle, M, Preminger, GM, Wu, QH, Chai, CA, Ghani, K, Maroccolo, M, Brehmer, M, Osther, PJ, Zawadzki, M, Tursunkulov, A, Kytaibekovich, MN, Abuvohidov, AA, Lara, CAR, Noori, Z, Zanetti, SP, Shrestha, S, de la Rosette, J, Denstedt, J, Ye, ZQ, Sarica, K, Choong, S. International Alliance of Urolithiasis (IAU) consensus on miniaturized percutaneous nephrolithotomy ( vol 11 , 70 , 2024). Military Medical Research. 2024; 11(1)DOI:10.1186/s40779-024-00579-8. PMID:39676164. IF:22.900(Q1/1D).
15/12/2024
Transient cerebral ischaemia alters mesenteric arteries in hypertensive rats: Limited reversal despite suberoylanilide hydroxamic acid cerebroprotection
Díaz-Pérez, A, Lope-Piedrafita, S, Pérez, B, Vázquez-Sufuentes, P, Rodriguez-Garcia, M, Briones, AM, Navarro, X, Penas, C, Jiménez-Altayó, F. Transient cerebral ischaemia alters mesenteric arteries in hypertensive rats: Limited reversal despite suberoylanilide hydroxamic acid cerebroprotection. LIFE SCIENCES. 2024; 359DOI:10.1016/j.lfs.2024.123247. PMID:39547431. IF:5.100(Q1/2D).
13/12/2024
A cross-sectional study of Phase I Clinical Trials authorized in Spain: An analysis of characteristics and times of execution based on experience
Filippi-Arriaga, F, Molina, P, Delgado-Espinoza, CE, Antonijoan, R. A cross-sectional study of Phase I Clinical Trials authorized in Spain: An analysis of characteristics and times of execution based on experience. MEDICINA CLINICA. 2024; 163(11)DOI:10.1016/j.medcli.2024.06.001. PMID:39043476. IF:2.100(Q2/3D).
13/12/2024
Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol
Fernandez-Camins, B, Vlacho, B, Canudas, A, Ortega, M, Granado-Casas, M, Perera-LLuna, A, Boluda-Sanson, A, El-Khattabi-Ofkir, Y, Franch-Nadal, J, Mauricio, D. Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol. BMJ Open. 2024; 14(12)DOI:10.1136/bmjopen-2023-083825. PMID:39675821. IF:2.300(Q2/3D).